Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia

• Status: Completed
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to determine whether treatment with quetiapine XR (Seroquel XR) tablets for 3 weeks will improve their agitation when they have acute psychosis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Quetiapine Fumarate

Criteria

Inclusion Criteria:

• Requirement for treatment of acute episode of schizophrenia (according to DSM-IV diagnostic criteria)

• PANSS total score of ³ 75

• CGI > 4

Exclusion Criteria:

• Any DSM-IV (Diagnostic and Statistical Manual of Mental Disorders 4th Edition) Axis I disorder not defined in the inclusion criteria

• Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others

• Substance or alcohol dependence at enrollment